Abstract
Background Clostridioides difficile infections (CDIs) are among the most prevalent hospital-associated infections (HAIs), particularly for intensive care unit (ICU) patients. The risks for developing active CDI from asymptomatic carriage of C. difficile are not well understood.
Methods We identified asymptomatic C. difficile carriage among 1897 ICU patients, using rectal swabs from an existing ICU vancomycin-resistant Enterococci (VRE) surveillance program. C. difficile isolates from VRE swabs, and from C. difficile-positive stool samples, were genome sequenced to assess clonal relationships among isolates from asymptomatic carriers and CDI patients. Integrated genomic and epidemiologic analyses identified multiple cases of asymptomatic carriers who developed CDI, and of asymptomatic transmission of C. difficile to naïve patients.
Results Genomic analyses identified diverse strains in infected patients and asymptomatic carriers. 7.4% of ICU patients asymptomatically carried C. difficile. 69% of isolates carried an intact toxin locus. In contrast, 96% of C. difficile stool isolates were toxigenic. CDI rates in asymptomatic carriers of toxigenic strains were 5.3%, versus 0.57% in non-carriers. The relative risk for CDI with asymptomatic carriage of a toxigenic strain was 9.32 (95% CI=3.25-26.7). Genomic identification of clonal clusters supported epidemiologic analyses for asymptomatic transmission events, with spatial-temporal overlaps identified in 13 of 28 cases.
Conclusions Our studies provide the first genomically-confirmed assessments of CDI relative risk from asymptomatic carriage of toxigenic strains and highlight the complex dynamics of asymptomatic transmission in ICUs. C. difficile screening can be implemented within existing HAI surveillance programs and, with isolation of asymptomatic carriers, has potential to reduce these risks.
Summary Relative risks for C. difficile infections rise to 9.32 in asymptomatic ICU patients carrying toxigenic strains. Integrated genomic and epidemiologic analyses illustrate functional use of C. difficile genomic data to identify asymptomatic transmission events and assist in outbreak investigations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the Hatch Family Foundation, the BWH Precision Medicine Institute, and NIDDK grant P30-DK034854. The work of Jay Worley was supported by the Intramural Research Program of the National Library of Medicine, National Institutes of Health.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The genomic datasets have been deposited into the NCBI Short Read Archive and are available in the NCBI Pathogen Detection Browser at https://ncbi.nlm.nih.gov/pathogens/isolates The C. difficile phylogeny created in this manuscript is available at https://itol.embl.de/tree/17022320725465491568233605
